Search research articles
Contact Us
Filters
Showing results (51-60 of 82) with videos related to
Page
of 9
Sort By:
Diagnostic and Prognostic Research
|
April 8, 2026
Protocol for the development and validation of a risk score to predict risk of adverse events associated with systemic anti-cancer treatment in late-stage lung cancer: Lung Cancer Improved Decisions (LUCID)
Ofran Almossawi, Luke Steventon, Ruth Keogh, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
October 6, 2021
Doxorubicin plus lurbinectedin in patients with advanced endometrial cancer: results from an expanded phase I study
Rebecca Kristeleit, Victor Moreno, Valentina Boni, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 5, 2020
De-Escalation After DE-ESCALATE and RTOG 1016: A Head and Neck Cancer InterGroup Framework for Future De-Escalation Studies
Hisham Mehanna, Danny Rischin, Stuart J Wong, et al.
BMJ Open
|
November 27, 2023
Protocol for the EACH trial: a multicentre phase II study evaluating the safety and antitumour activity of the combination of avelumab, an anti-PD-L1 agent, and cetuximab, as any line treatment for patients with recurrent/metastatic head and neck squamous cell cancer (HNSCC) in the UK
Kenrick Ng, Rob Metcalf, Joseph Sacco, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 18, 2018
Patritumab with Cetuximab plus Platinum-Containing Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: An Open-Label, Phase Ib Study
Magnus T Dillon, Lorna Grove, Kate L Newbold, et al.
Lung Cancer (Amsterdam, Netherlands)
|
May 12, 2018
A phase I study of nintedanib combined with cisplatin/gemcitabine as first-line therapy for advanced squamous non-small cell lung cancer (LUME-Lung 3)
Martin Forster, Allan Hackshaw, Tommaso De Pas, et al.
BMJ Open
|
March 19, 2020
Phase I trial of WEE1 inhibition with chemotherapy and radiotherapy as adjuvant treatment, and a window of opportunity trial with cisplatin in patients with head and neck cancer: the <b>WISTERIA</b> trial protocol
Anthony Kong, James Good, Amanda Kirkham, et al.
Science (New York, N.Y.)
|
April 20, 2002
Murine leukemia induced by retroviral gene marking
Zhixiong Li, Jochen Düllmann, Bernd Schiedlmeier, et al.
BMJ Open
|
April 19, 2018
Study protocol for the SARON trial: a multicentre, randomised controlled phase III trial comparing the addition of stereotactic ablative radiotherapy and radical radiotherapy with standard chemotherapy alone for oligometastatic non-small cell lung cancer
John Conibear, Brendan Chia, Yenting Ngai, et al.
ESMO Open
|
June 28, 2019
Prospective analysis of 895 patients on a UK Genomics Review Board
David Allan Moore, Marina Kushnir, Gabriel Mak, et al.
Page
of 9
Search research articles
Search
Showing results (51-60 of 82) with videos related to
Sort By:
Page
of 9
Diagnostic and Prognostic Research
|
April 8, 2026
Protocol for the development and validation of a risk score to predict risk of adverse events associated with systemic anti-cancer treatment in late-stage lung cancer: Lung Cancer Improved Decisions (LUCID)
Ofran Almossawi, Luke Steventon, Ruth Keogh, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
October 6, 2021
Doxorubicin plus lurbinectedin in patients with advanced endometrial cancer: results from an expanded phase I study
Rebecca Kristeleit, Victor Moreno, Valentina Boni, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 5, 2020
De-Escalation After DE-ESCALATE and RTOG 1016: A Head and Neck Cancer InterGroup Framework for Future De-Escalation Studies
Hisham Mehanna, Danny Rischin, Stuart J Wong, et al.
BMJ Open
|
November 27, 2023
Protocol for the EACH trial: a multicentre phase II study evaluating the safety and antitumour activity of the combination of avelumab, an anti-PD-L1 agent, and cetuximab, as any line treatment for patients with recurrent/metastatic head and neck squamous cell cancer (HNSCC) in the UK
Kenrick Ng, Rob Metcalf, Joseph Sacco, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 18, 2018
Patritumab with Cetuximab plus Platinum-Containing Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: An Open-Label, Phase Ib Study
Magnus T Dillon, Lorna Grove, Kate L Newbold, et al.
Lung Cancer (Amsterdam, Netherlands)
|
May 12, 2018
A phase I study of nintedanib combined with cisplatin/gemcitabine as first-line therapy for advanced squamous non-small cell lung cancer (LUME-Lung 3)
Martin Forster, Allan Hackshaw, Tommaso De Pas, et al.
BMJ Open
|
March 19, 2020
Phase I trial of WEE1 inhibition with chemotherapy and radiotherapy as adjuvant treatment, and a window of opportunity trial with cisplatin in patients with head and neck cancer: the <b>WISTERIA</b> trial protocol
Anthony Kong, James Good, Amanda Kirkham, et al.
Science (New York, N.Y.)
|
April 20, 2002
Murine leukemia induced by retroviral gene marking
Zhixiong Li, Jochen Düllmann, Bernd Schiedlmeier, et al.
BMJ Open
|
April 19, 2018
Study protocol for the SARON trial: a multicentre, randomised controlled phase III trial comparing the addition of stereotactic ablative radiotherapy and radical radiotherapy with standard chemotherapy alone for oligometastatic non-small cell lung cancer
John Conibear, Brendan Chia, Yenting Ngai, et al.
ESMO Open
|
June 28, 2019
Prospective analysis of 895 patients on a UK Genomics Review Board
David Allan Moore, Marina Kushnir, Gabriel Mak, et al.
Page
of 9